Activin and Inhibin

GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase ( SCD ) inhibitor extracted from patent WO/2009060053 A1, compound example 16.In VitroGSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD), which can be used to treat and/or

GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase ( SCD ) inhibitor extracted from patent WO/2009060053 A1, compound example 16.In VitroGSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD), which can be used to treat and/or

GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH) . GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC 50 s of 27, 61 and 189 pM, respectively.

GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC 50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary diseaseIn VitroGSK256066

GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC 50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary diseaseIn VitroGSK256066

GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC 50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary diseaseIn VitroGSK256066

GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC 50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary diseaseIn VitroGSK256066

GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3In VitroGSK2593074A (GSK’074: 0.01, 0.1, 1, 10, and 100 nM: 6 hours for MOVAS cells: 3 hours for L929 cells) completely rescues cells from necroptosis

GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3In VitroGSK2593074A (GSK’074: 0.01, 0.1, 1, 10, and 100 nM: 6 hours for MOVAS cells: 3 hours for L929 cells) completely rescues cells from necroptosis

GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3In VitroGSK2593074A (GSK’074: 0.01, 0.1, 1, 10, and 100 nM: 6 hours for MOVAS cells: 3 hours for L929 cells) completely rescues cells from necroptosis

GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3In VitroGSK2593074A (GSK’074: 0.01, 0.1, 1, 10, and 100 nM: 6 hours for MOVAS cells: 3 hours for L929 cells) completely rescues cells from necroptosis

GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3In VitroGSK2593074A (GSK’074: 0.01, 0.1, 1, 10, and 100 nM: 6 hours for MOVAS cells: 3 hours for L929 cells) completely rescues cells from necroptosis